Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study

BackgroundThe present study was conducted to analyze the clinical efficacy and safety of sintilimab as second-line or above therapy for patients with advanced or metastatic gastric cancer.MethodsPatients with advanced or metastatic gastric cancer that progressed after prior systemic therapies and tr...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Caiyun Nie, Huifang Lv, Yingjun Liu, Beibei Chen, Weifeng Xu, Jianzheng Wang, Xiaobing Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-09-01
coleção:	Frontiers in Oncology
Assuntos:	gastric/gastroesophageal junction adenocarcinoma sintilimab immunotherapy efficacy Lauren classification
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2021.741865/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!